• 
• 
• 
• 
  • Ogłoszenia
  • Plan wydawniczy
  • Regulamin ogłaszania prac
  • Zasady recenzowania i recenzenci
• 
• 
• 
• 

Wydanie 4/2006

Avastin - nowa nadzieja w okulistyce?

Avastin - New Hope in Ophthalmology?

Agnieszka Nowosielska, Iwona Grabska-Liberek, Katarzyna Gurdziel

Oddział Kliniczny Okulistyki Centrum Medycznego Kształcenia Podyplomowego Samodzielnego Publicznego Szpitala Klinicznego im. prof. W. Orłowskiego w Warszawie P.o. kierownik: dr n. med. Iwona Grabska-Liberek

Summary: Bevacizumab (Avastin ) is a full - length, humanized, monoclonal antibody directed against vascular endothelial growth factor A (VEGF-A). Bevacizumab was the first anti-VEGF drug approved by FDA for the treatment of colorectal cancer. Intravenous chemotherapy combined with bevacizumab has shown promising results and has been used in many more oncology indications now. VEGF is considered to be the one of the major stimuli for neovascularization and macular edema responsible for wet AMD, diabetic retinopathy and neovascular glaucoma. The role of VEGF in those disorders has been shown as a result of clinical trial with anti-VEGF drug known as pegaptanib (Macugen). In 2004, first trial with Avastin used in the treatment of wet AMD was launched in Bascom Palmer Eye Institute, Miami, USA. SANA Trial (Systemic Avastin for Neovascular AMD) has shown good results both as far as safety and efficacy of the treatment were concerned. Intravitreal bevacizumab has now been given for a few years. It has shown very promising results and it turned out to be relatively safe when given locally. It is also much cheaper than other approved anti-VEGF ophthalmic therapy. But we still do not know if it is going to be our magic drug?

Keywords: Avastin, Bevacizumab, AMD, diabetic retinopathy, retinal vein occlusion, neovascular glaucoma, VEGF (vascular endothelial growth factor).

powrót